Evidence map›Paper›PMID 42548672›Full record

ArticleFrontiers in immunology2026

Outcomes and predictors of second haploidentical hematopoietic stem cell transplantation for pediatric acute leukemia relapsing after a first allograft.

Kai Chen, Huifang Wang, Qing Liu, Guanhua Hu, Zhang Feng, Bing Zou, Yingxi Zuo, Lu Bai, Pan Suo, Jingbo Shao and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Kai Chen *Department of Hematology and Oncology, Shanghai Children's Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Huifang Wang *Peking University People's Hospital & Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
Qing LiuDepartment of Hematology and Oncology, Shanghai Children's Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Guanhua HuPeking University People's Hospital & Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
Zhang FengPeking University People's Hospital & Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
Bing ZouDepartment of Hematology and Oncology, Shanghai Children's Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Yingxi ZuoPeking University People's Hospital & Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
Lu BaiPeking University People's Hospital & Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
Pan SuoPeking University People's Hospital & Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
Jingbo ShaoDepartment of Hematology and Oncology, Shanghai Children's Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Hui JiangDepartment of Hematology and Oncology, Shanghai Children's Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Xiaohui ZhangPeking University People's Hospital & Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
Xiaojun HuangPeking University People's Hospital & Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
Jinjin ChenDepartment of Child Health Care, Shanghai Children's Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Yifei ChengPeking University People's Hospital & Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The clinical efficacy and prognostic factors of haploidentical hematopoietic stem cell transplantation (haplo-HSCT) as a salvage approach for children with relapsed acute leukemia (AL) after a first allogeneic HSCT (allo-HSCT) remain unclear. This study aimed to evaluate the clinical efficacy, survival outcomes, and prognostic factors of second haploidentical HSCT in children with relapsed AL following prior allo-HSCT. Methods: This retrospective study included 40 pediatric patients (median age: 8.5 years) who underwent a second haplo-HSCT at two Chinese transplantation centers between January 2017 and December 2023. The primary endpoints were overall survival (OS) and leukemia-free survival (LFS); and secondary endpoints included cumulative relapse incidence and non-relapse mortality (NRM). Results: With a median follow-up of 16.0 months, 1- and 2-year OS rates were 77.8% and 65.5%, and LFS rates were 72.4% and 61.0%, respectively. The 2-year cumulative incidences of relapse and NRM were 26.6% and 15.1%, respectively. Multivariate analysis showed that B-cell acute lymphoblastic leukemia was associated with the most favorable 2-year OS (HR = 0.081, 95%CI: 0.007-0.877, P = 0.039). Grade III-IV acute GVHD occurred in 25.0% of patients, and chronic GVHD occurred in 50.0% (10.0% extensive). Conclusions: These findings suggest that second haplo-HSCT with myeloablative conditioning may be a viable and effective salvage option for pediatric patients with relapsed AL lacking matched donors, possibly through graft-versus-leukemia effects. Future studies should incorporate targeted therapies and immune modulation strategies to improve outcomes in this high-risk population.

Indexed as

Hematopoietic Stem Cell TransplantationPrecursor Cell Lymphoblastic Leukemia-LymphomaTransplantation, HaploidenticalAdolescentAllograftsChildChild, PreschoolFemaleGraft vs Host DiseaseHumansInfantMalePrognosisRecurrenceRetrospective StudiesSalvage Therapygraft-versus-leukemia effecthaploidentical hematopoietic stem cell transplantation (haplo-HSCT)pediatric relapsed acute leukemiaprognostic factorssecond allogeneic transplantationsurvival outcomes

Identifiers

PMID42548672
PMCPMC13429505

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.